Floatz logo

Geptanolimab

Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma

Genor Biopharma Co., Ltd.monoclonal_antibodyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Northwestern University
Phase 3BB
FILGRASTIM
National Cancer Institute (NCI)
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 3BB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 3BB

View all 22 →

Same molecule, other indications

Geptanolimab is also rated in:

B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →